Meenu Chhabra - Net Worth and Insider Trading

Meenu Chhabra Net Worth

The estimated net worth of Meenu Chhabra is at least $4,474 dollars as of 2024-05-10. Meenu Chhabra is the President and CEO of Proteostasis Therapeutics Inc and owns about 4,031 shares of Proteostasis Therapeutics Inc (PTI) stock worth over $4,474. Details can be seen in Meenu Chhabra's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Meenu Chhabra has not made any transactions after 2019-02-04 and currently still holds the listed stock(s).

Transaction Summary of Meenu Chhabra

Meenu Chhabra Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Meenu Chhabra owns 8 companies in total, including Proteostasis Therapeutics Inc (PTI) , Yumanity Therapeutics Inc (YMTX) , and Vallon Pharmaceuticals Inc (VLON) among others .

Click here to see the complete history of Meenu Chhabra’s form 4 insider trades.

Insider Ownership Summary of Meenu Chhabra

Ticker	Comapny	Transaction Date	Type of Owner
PTI	Proteostasis Therapeutics Inc	2020-03-02	director & President and CEO
YMTX	Yumanity Therapeutics Inc	2016-02-10	director & President and CEO
VLON	Vallon Pharmaceuticals Inc	2022-02-23	director
		2022-07-29	director
		2023-01-03	director
		2016-02-10	director & President and CEO
		2022-02-23	director
		2022-07-29	director

Meenu Chhabra Latest Holdings Summary

Meenu Chhabra currently owns a total of 1 stock. Meenu Chhabra owns 4,031 shares of Proteostasis Therapeutics Inc (PTI) as of February 4, 2019, with a value of $4,474.

Latest Holdings of Meenu Chhabra

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PTI	Proteostasis Therapeutics Inc	2019-02-04	4,031	1.11	4,474

Holding Weightings of Meenu Chhabra

Meenu Chhabra Form 4 Trading Tracker

According to the SEC Form 4 filings, Meenu Chhabra has made a total of 0 transactions in Proteostasis Therapeutics Inc (PTI) over the past 5 years. The most-recent trade in Proteostasis Therapeutics Inc is the sale of 824 shares on February 4, 2019, which brought Meenu Chhabra around $49,269.

Insider Trading History of Meenu Chhabra

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Meenu Chhabra Trading Performance

GuruFocus tracks the stock performance after each of Meenu Chhabra's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Meenu Chhabra is 63.09%. GuruFocus also compares Meenu Chhabra's trading performance to market benchmark return within the same time period. The performance of stocks bought by Meenu Chhabra within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Meenu Chhabra's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Meenu Chhabra

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-4.92
Relative Return to S&P 500(%)	-8.93

Meenu Chhabra Ownership Network

Ownership Network List of Meenu Chhabra

No Data

Ownership Network Relation of Meenu Chhabra

Meenu Chhabra Owned Company Details

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Meenu Chhabra is the director & President and CEO of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , Chief Scientific Officer Benito Munoz , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Meenu Chhabra is the director & President and CEO of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

Over the past 18 months, Meenu Chhabra made no insider transaction in Yumanity Therapeutics Inc (YMTX). Other recent insider transactions involving Yumanity Therapeutics Inc (YMTX) include a net sale of 10,890 shares made by Richard Peters , a net sale of 3,116 shares made by Michael D Wyzga , and a net sale of 3,116 shares made by Devin Whittemore Smith .

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 19,098 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 19,098 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Vallon Pharmaceuticals Inc do?

Who are the key executives at Vallon Pharmaceuticals Inc?

Meenu Chhabra is the director of Vallon Pharmaceuticals Inc. Other key executives at Vallon Pharmaceuticals Inc include Chief Financial Officer Leanne M. Kelly , director & Chief Executive Officer David Charles Baker , and 10 percent owner Arcturus Therapeutics Holdings Inc. .

Vallon Pharmaceuticals Inc (VLON) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vallon Pharmaceuticals Inc (VLON) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vallon Pharmaceuticals Inc (VLON) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vallon Pharmaceuticals Inc (VLON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vallon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Apexigen Inc do?

Who are the key executives at Apexigen Inc?

Meenu Chhabra is the director of Apexigen Inc. Other key executives at Apexigen Inc include Chief Operating Officer Francis Willard Sarena , Chief Medical Officer Frank J. Hsu , and Chief Financial Officer William E. Duke .

Apexigen Inc (APGN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Apexigen Inc (APGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Apexigen Inc (APGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Apexigen Inc (APGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Apexigen Inc Insider Transactions

No Available Data

What does Macrogenics Inc do?

Who are the key executives at Macrogenics Inc?

Meenu Chhabra is the director of Macrogenics Inc. Other key executives at Macrogenics Inc include Acting General Counsel Jeffrey Stuart Peters , SVP & CFO and Secretary James Karrels , and Sr VP & BPD & Manufacturing Thomas Spitznagel .

Macrogenics Inc (MGNX) Insider Trades Summary

Over the past 18 months, Meenu Chhabra made no insider transaction in Macrogenics Inc (MGNX). Other recent insider transactions involving Macrogenics Inc (MGNX) include a net purchase of 1,700,000 shares made by Biotech Target N V , a net sale of 168,767 shares made by Jeffrey Stuart Peters , and a net sale of 48,846 shares made by Ezio Bonvini .

In summary, during the past 3 months, insiders sold 168,303 shares of Macrogenics Inc (MGNX) in total and bought 0 shares, with a net sale of 168,303 shares. During the past 18 months, 298,772 shares of Macrogenics Inc (MGNX) were sold and 1,715,000 shares were bought by its insiders, resulting in a net purchase of 1,416,228 shares.

Macrogenics Inc (MGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Macrogenics Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Meenu Chhabra is the director & President and CEO of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KA) Insider Trades Summary

Over the past 18 months, Meenu Chhabra made no insider transaction in Kineta Inc (KA). Other recent insider transactions involving Kineta Inc (KA) include a net purchase of 12,301 shares made by Shawn Iadonato , a net purchase of 7,250 shares made by Raymond J. Bartoszek , and a net purchase of 4,397 shares made by Craig W. Philips .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,113 shares of Kineta Inc (KA) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 44,137 shares.

Kineta Inc (KA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

What does GRI Bio Inc do?

Who are the key executives at GRI Bio Inc?

Meenu Chhabra is the director of GRI Bio Inc. Other key executives at GRI Bio Inc include Chief Medical Officer Albert Agro , director & 10 percent owner & Chief Executive Officer Walter Marc Hertz , and Chief Scientific Officer Vipin Chaturvedi .

GRI Bio Inc (GRI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of GRI Bio Inc (GRI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of GRI Bio Inc (GRI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

GRI Bio Inc (GRI)'s detailed insider trading history can be found in Insider Trading Tracker table.

GRI Bio Inc Insider Transactions

No Available Data

What does Brookline Capital Acquisition Corp do?

Who are the key executives at Brookline Capital Acquisition Corp?

Meenu Chhabra is the director of Brookline Capital Acquisition Corp. Other key executives at Brookline Capital Acquisition Corp include Chief Operating Officer Francis Willard Sarena , Chief Medical Officer Frank J. Hsu , and Chief Financial Officer William E. Duke .

Brookline Capital Acquisition Corp (BCACU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Brookline Capital Acquisition Corp (BCACU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Brookline Capital Acquisition Corp (BCACU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Brookline Capital Acquisition Corp (BCACU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Brookline Capital Acquisition Corp Insider Transactions

No Available Data

Meenu Chhabra Mailing Address

Above is the net worth, insider trading, and ownership report for Meenu Chhabra. You might contact Meenu Chhabra via mailing address: C/o Vallon Pharamceuticals, Inc., 100 N 18th, Street, Suite 300, Philadelphia Pa 19103.

Discussions on Meenu Chhabra

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.